Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists

The extracellular domain of tumor necrosis factor receptors (TNFR) generally require assembly into a homotrimeric quaternary structure as a prerequisite for initiation of signaling via the cytoplasmic domains. TNF receptor homotrimers are natively activated by similarly homo-trimerized TNF ligands,...

Full description

Bibliographic Details
Main Authors: George Fromm, Suresh de Silva, Taylor H. Schreiber
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1236332/full
_version_ 1797680789089943552
author George Fromm
Suresh de Silva
Taylor H. Schreiber
author_facet George Fromm
Suresh de Silva
Taylor H. Schreiber
author_sort George Fromm
collection DOAJ
description The extracellular domain of tumor necrosis factor receptors (TNFR) generally require assembly into a homotrimeric quaternary structure as a prerequisite for initiation of signaling via the cytoplasmic domains. TNF receptor homotrimers are natively activated by similarly homo-trimerized TNF ligands, but can also be activated by synthetic agonists including engineered antibodies and Fc-ligand fusion proteins. A large body of literature from pre-clinical models supports the hypothesis that synthetic agonists targeting a diverse range of TNF receptors (including 4-1BB, CD40, OX40, GITR, DR5, TNFRSF25, HVEM, LTβR, CD27, and CD30) could amplify immune responses to provide clinical benefit in patients with infectious diseases or cancer. Unfortunately, however, the pre-clinical attributes of synthetic TNF receptor agonists have not translated well in human clinical studies, and have instead raised fundamental questions regarding the intrinsic biology of TNF receptors. Clinical observations of bell-shaped dose response curves have led some to hypothesize that TNF receptor overstimulation is possible and can lead to anergy and/or activation induced cell death of target cells. Safety issues including liver toxicity and cytokine release syndrome have also been observed in humans, raising questions as to whether those toxicities are driven by overstimulation of the targeted TNF receptor, a non-TNF receptor related attribute of the synthetic agonist, or both. Together, these clinical findings have limited the development of many TNF receptor agonists, and may have prevented generation of clinical data which reflects the full potential of TNF receptor agonism. A number of recent studies have provided structural insights into how different TNF receptor agonists bind and cluster TNF receptors, and these insights aid in deconvoluting the intrinsic biology of TNF receptors with the mechanistic underpinnings of synthetic TNF receptor agonist therapeutics.
first_indexed 2024-03-11T23:35:22Z
format Article
id doaj.art-d26358ed7a8b47949f8d91edef645792
institution Directory Open Access Journal
issn 1664-3224
language English
last_indexed 2024-03-11T23:35:22Z
publishDate 2023-09-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj.art-d26358ed7a8b47949f8d91edef6457922023-09-20T04:35:04ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-09-011410.3389/fimmu.2023.12363321236332Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonistsGeorge FrommSuresh de SilvaTaylor H. SchreiberThe extracellular domain of tumor necrosis factor receptors (TNFR) generally require assembly into a homotrimeric quaternary structure as a prerequisite for initiation of signaling via the cytoplasmic domains. TNF receptor homotrimers are natively activated by similarly homo-trimerized TNF ligands, but can also be activated by synthetic agonists including engineered antibodies and Fc-ligand fusion proteins. A large body of literature from pre-clinical models supports the hypothesis that synthetic agonists targeting a diverse range of TNF receptors (including 4-1BB, CD40, OX40, GITR, DR5, TNFRSF25, HVEM, LTβR, CD27, and CD30) could amplify immune responses to provide clinical benefit in patients with infectious diseases or cancer. Unfortunately, however, the pre-clinical attributes of synthetic TNF receptor agonists have not translated well in human clinical studies, and have instead raised fundamental questions regarding the intrinsic biology of TNF receptors. Clinical observations of bell-shaped dose response curves have led some to hypothesize that TNF receptor overstimulation is possible and can lead to anergy and/or activation induced cell death of target cells. Safety issues including liver toxicity and cytokine release syndrome have also been observed in humans, raising questions as to whether those toxicities are driven by overstimulation of the targeted TNF receptor, a non-TNF receptor related attribute of the synthetic agonist, or both. Together, these clinical findings have limited the development of many TNF receptor agonists, and may have prevented generation of clinical data which reflects the full potential of TNF receptor agonism. A number of recent studies have provided structural insights into how different TNF receptor agonists bind and cluster TNF receptors, and these insights aid in deconvoluting the intrinsic biology of TNF receptors with the mechanistic underpinnings of synthetic TNF receptor agonist therapeutics.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1236332/fullTNF superfamilyagonistTNF receptorTNF ligandCD4041BB
spellingShingle George Fromm
Suresh de Silva
Taylor H. Schreiber
Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists
Frontiers in Immunology
TNF superfamily
agonist
TNF receptor
TNF ligand
CD40
41BB
title Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists
title_full Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists
title_fullStr Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists
title_full_unstemmed Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists
title_short Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists
title_sort reconciling intrinsic properties of activating tnf receptors by native ligands versus synthetic agonists
topic TNF superfamily
agonist
TNF receptor
TNF ligand
CD40
41BB
url https://www.frontiersin.org/articles/10.3389/fimmu.2023.1236332/full
work_keys_str_mv AT georgefromm reconcilingintrinsicpropertiesofactivatingtnfreceptorsbynativeligandsversussyntheticagonists
AT sureshdesilva reconcilingintrinsicpropertiesofactivatingtnfreceptorsbynativeligandsversussyntheticagonists
AT taylorhschreiber reconcilingintrinsicpropertiesofactivatingtnfreceptorsbynativeligandsversussyntheticagonists